SCYX Insider Buying: Tinmouth Brian Philippe Acquires Shares
Tinmouth Brian Philippe added 2,875 shares to his SCYX holdings on June 26, 2026.
Key Points
- Tinmouth Brian Philippe bought 2,875 shares of SCYX on June 26, 2026, with shares trading at $4.07 on Wednesday.
- Several institutional investors, including Squadron Capital Management and Vanguard Capital Management, opened new positions in SCYX.
- Analysts from Guggenheim and Ladenburg Thalmann maintain a 'buy' rating on SCYX, with price targets ranging from $3.00 to $15.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Tinmouth Brian Philippe recently purchased 2,875 shares of SCYX on June 26, 2026. This insider transaction comes as the stock traded at $4.07 on Wednesday.
Other Institutional Activity in SCYX
Several institutional investors have shown interest in SCYX. Squadron Capital Management LLC opened a new position with 7,608,695 shares valued at approximately $6,976,412. Heights Capital Management, Inc followed suit, acquiring 2,086,960 shares worth about $1,913,534. Meanwhile, Avidity Partners Management LP held steady with 2,081,660 shares, showing no change in their position. Kingdon Capital Management, L.L.C. also initiated a new stake with 1,982,491 shares valued at $1,817,746. Additionally, Empery Asset Management, LP and Vanguard Capital Management LLC each opened new positions, holding 1,847,826 and 1,564,398 shares, respectively.
SCYNEXIS, Inc. Stock Down 22.2%
Shares of SCYX traded near $4.07 on Wednesday. The company, known for its work in developing anti-infective therapies, has attracted attention from both insiders and institutional investors alike.
$SCYX stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at SCYNEXIS, Inc.
On June 26, 2026, several insiders, including Armando Anido, Ann Hanham, and David Hastings, each purchased 2,875 shares of SCYX. These transactions were not part of a pre-planned trading program, indicating personal investment decisions.
Analysts Set New Price Targets
Analysts continue to show confidence in SCYX. On October 28, 2025, Guggenheim maintained its 'buy' rating with a price target of $3.00. Ladenburg Thalmann & Co. also reiterated its 'buy' stance, setting a $7.50 target on May 10, 2024. Maxim Group, on August 16, 2023, reiterated a 'buy' rating with a higher target of $10.00.
Bottom Line
The recent insider buying activity in SCYX, alongside new positions from institutional investors, suggests growing interest in the company. Analyst ratings reinforce this sentiment, maintaining 'buy' recommendations with varied price targets. As always, remember that insider and institutional activities provide insights into market sentiment, but past actions do not predict future performance.
Get SCYNEXIS, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SCYX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.